Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Asterias, Cancer Research UK ink deal for new lung cancer vaccine Asterias Biotherapeutics, a subsidiary of BioTime, has entered into an agreement with Cancer Research Technology (CRT), Cancer Research UK's development and commercialization arm, to evaluate its AST-VAC2 in a clinical trial as an immunotherapy to treat patients with non-small cell lung cancer (NSCLC). Contract Research & Services > Clinical Trials > News
Cellerant gets $47.5m contract to support development of CLT-008 By PBR Staff Writer
US-based biotechnology firm Cellerant Therapeutics has received $47.5m contract under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) to support the continued advanced development of CLT-008.
Drug Research > Drug Discovery & Development > News FDA approves Takeda and Orexigen's Contrave for chronic weight management By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals USA and Orexigen Therapeutics’ Contrave (naltrexone HCI and bupropion HCI) extended-release tablets for chronic weight management.
Regulatory Affairs > News NeoStem enters into license deal with Rockefeller University to expand cancer immunotherapy NeoStem (NBS), a leader in the emerging cellular therapy industry, announced that the Company has entered into an exclusive license agreement with The Rockefeller University for patented technologies that further expand the Company's intellectual property portfolio associated with its Targeted Cancer Immunotherapy Program.
Automation > IT & Software > News
Prosonix confirms potential of MCP Technology to develop new FDC therapies for respiratory diseases Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that it has confirmed the potential of its Multi-component Particle (MCP) Technology for creating novel inhaled, dual and triple fixed dose combination (FDC) therapies for respiratory diseases.
Automation > IT & Software > News Marina Biotech announces continued worldwide expansion of Delivery Technology Intellectual Property Estate Marina Biotech, a leading nucleic acid-based drug discovery and development company focused on rare diseases, had received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering the following delivery technologies: SMARTICLES in Europe; TransKingdom RNA interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China.
Automation > IT & Software > News Grafix randomized controlled clinical trial recognized as high quality DFU trial in recent wounds supplement Osiris Therapeutics (OSIR) has announced the release of a dedicated supplement in Wounds, a peer-reviewed journal focusing on wound care and wound research, based on the proceedings of a CME accredited program entitled Advances In Wound Therapy: Understanding Differences Between Cellular And Acellular Therapies in the Treatment of Chronic Wounds at the 2014 Spring Symposium on Advanced Wound Care (SAWC) in Orlando.
Production & Manufacturing > OTC > News

Latest News and Insight by Sector

Production & Manufacturing

Grafix randomized controlled clinical trial recognized as high quality DFU trial in recent wounds supplement
Osiris Therapeutics (OSIR) has announced the release of a dedicated supplement in Wounds, a peer-reviewed journal focusing on wound care and wound research, based on the proceedings of a CME accredited program entitled Advances In Wound Therapy: Understanding Differences Between Cellular And Acellular Therapies in the Treatment of Chronic Wounds at the 2014 Spring Symposium on Advanced Wound Care (SAWC) in Orlando.
Production & Manufacturing > OTC > News
Lakewood-Amedex gets notice of allowance from USPTO for new patent covering nanoRNA gene-silencing technology
Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued a 'Notice of Allowance' for patent application 11/673,486 entitled 'Oligonucleotide-Containing Pharmacological Compositions And Their Uses'.
Production & Manufacturing > Process & Production > News

Drug Research

Cellerant gets $47.5m contract to support development of CLT-008
By PBR Staff Writer
US-based biotechnology firm Cellerant Therapeutics has received $47.5m contract under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) to support the continued advanced development of CLT-008.
Drug Research > Drug Discovery & Development > News
Oxygen Biotherapeutics halts Phase IIb traumatic brain injury trial of Oxycyte
By PBR Staff Writer
Oxygen Biotherapeutics has decided to stop the current Phase IIb trial of its drug candidate Oxycyte indicated for the treatment of patients with traumatic brain injury.
Drug Research > Drug Delivery > News

Inward Investment

Janssen's Cilag International acquires biopharmaceutical firm Covagen
By PBR Staff Writer
Janssen Pharmaceutical's affiliate Cilag International has completed the acquisition of Covagen, Swiss biopharmaceutical firm specializing in the development of multispecific protein therapeutics through its FynomAb technology platform.
News
Recipharm to buy Corvette Pharmaceutical Services for $160m
By PBR Staff Writer
Swedish contract development and manufacturing organisation Recipharm has agreed to purchase Milan based Corvette Pharmaceutical Services Group (Corvette) from Italian private equity group LBO Italia Investimenti.
Contract Research & Services > Contract Research > News

Packaging

Biologics adds frozen storage capabilities to clinical research services
By PBR Staff Writer
Biologics’ Clinical Research Services has announced the addition of frozen storage capabilities to its state-of-the-art facilities and cold-chain packaging and distribution.
Packaging > News
ATMI, D-Lab launch new Sterile Pyrofree vials
By PBR Staff Writer
US-based technology firm ATMI in partnership with Disposable Lab (D-Lab), a French contract-manufacturing company, has launched a line of pyrogen-free vials in order to meet biopharmaceutical filling and final packaging needs.
Packaging > News

Contract Research & Services

Asterias, Cancer Research UK ink deal for new lung cancer vaccine
By PBR Staff Writer
Asterias Biotherapeutics, a subsidiary of BioTime, has entered into an agreement with Cancer Research Technology (CRT), Cancer Research UK's development and commercialization arm, to evaluate its AST-VAC2 in a clinical trial as an immunotherapy to treat patients with non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
G1 Therapeutics begins Phase I clinical trial of G1T28-1 for several oncology indications
By PBR Staff Writer
US-based pharmaceutical firm G1 Therapeutics has started a randomized, placebo-controlled, single ascending dose Phase I clinical trial of G1T28-1, a highly potent and selective CDK4/6 inhibitor with broad potential in multiple oncology indications.
Contract Research & Services > Clinical Trials > News

Automation

NeoStem enters into license deal with Rockefeller University to expand cancer immunotherapy
NeoStem (NBS), a leader in the emerging cellular therapy industry, announced that the Company has entered into an exclusive license agreement with The Rockefeller University for patented technologies that further expand the Company's intellectual property portfolio associated with its Targeted Cancer Immunotherapy Program.
Automation > IT & Software > News
Prosonix confirms potential of MCP Technology to develop new FDC therapies for respiratory diseases
Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that it has confirmed the potential of its Multi-component Particle (MCP) Technology for creating novel inhaled, dual and triple fixed dose combination (FDC) therapies for respiratory diseases.
Automation > IT & Software > News

Regulatory Affairs

FDA approves Takeda and Orexigen's Contrave for chronic weight management
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals USA and Orexigen Therapeutics’ Contrave (naltrexone HCI and bupropion HCI) extended-release tablets for chronic weight management.
Regulatory Affairs > News
FDA grants orphan drug status for Viamet's VT-1129 to treat cryptococcal meningitis
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted orphan drug designation for Viamet Pharmaceuticals' VT-1129, a potent and selective, oral, antifungal agent, to treat cryptococcal meningitis, a life-threatening invasive fungal infection of the lining of the brain and spinal cord.
Regulatory Affairs > News

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Reports Buy online from $250



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery